CAPZB mRNA is a novel biomarker for cervical high-grade squamous lesions.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

RNA, Messenger*/genetics ; Biomarkers, Tumor*/genetics ; Uterine Cervical Neoplasms*/genetics ; Uterine Cervical Neoplasms*/diagnosis ; Uterine Cervical Neoplasms*/pathology ; In Situ Hybridization, Fluorescence*/methods ; DNA Methylation*; Humans ; Female ; Adult ; Middle Aged ; CapZ Actin Capping Protein/genetics ; CapZ Actin Capping Protein/metabolism ; Squamous Intraepithelial Lesions of the Cervix/genetics ; Squamous Intraepithelial Lesions of the Cervix/pathology ; Squamous Intraepithelial Lesions of the Cervix/diagnosis ; Squamous Intraepithelial Lesions of the Cervix/metabolism ; ROC Curve

This study aimed to evaluate the potential of capping protein (actin filament) muscle Z-line subunit β (CAPZB) messenger ribonucleic acid (mRNA) levels as a biomarker for distinguishing low-grade squamous intraepithelial lesions of the cervix (LSIL) from high-grade squamous intraepithelial lesions of the cervix (HSIL). We collected a total of 166 cervical exfoliated cells and divided them into five groups based on histopathological results. Each sample was divided into two portions, one for fluorescence in situ hybridization (FISH) detection and the other for bisulfite sequencing polymerase chain reaction (BSP) detection. We found that FISH detection of CAPZB mRNA mean fluorescence intensity (MFI) and BSP detection of CAPZB deoxyribonucleic acid (DNA) percentage of methylation rate (PMR) performed as biomarkers for distinguishing HSIL from LSIL, with an area under the receiver operating characteristic curve (AUC), sensitivity, specificity and cut-off value of 0.893, 81.25%, 80.39% and 0.616, 0.794, 64.06%, 81.37% and 0.454, respectively. Furthermore, FISH detection of CAPZB mRNA exhibited a greater AUC (0.893) for the detection of HSIL than the CAPZB DNA methylation method (0.794), indicating the CAPZB mRNA levels can be used as a biomarker for assessing cervical lesions.
(© 2024. The Author(s).)

Open Biol. 2021 Jan;11(1):200358. (PMID: 33465324)
J Biochem. 1968 Aug;64(2):263-5. (PMID: 5715509)
Infect Genet Evol. 2021 Sep;93:104921. (PMID: 34004362)
Int J Mol Sci. 2024 Jun 28;25(13):. (PMID: 39000261)
Cell Commun Signal. 2020 Aug 8;18(1):121. (PMID: 32771000)
Nat Cell Biol. 2017 Jun;19(6):689-697. (PMID: 28530659)
Cells. 2020 Mar 05;9(3):. (PMID: 32150897)
Mod Pathol. 2022 Jul;35(7):858-864. (PMID: 35256738)
Mol Cancer. 2020 Aug 27;19(1):132. (PMID: 32854710)
J Biol Eng. 2024 Jul 26;18(1):42. (PMID: 39061076)
Life Sci Alliance. 2022 Jan 7;5(4):. (PMID: 34996842)
Mol Cancer. 2021 Mar 5;20(1):49. (PMID: 33673851)
Am J Respir Cell Mol Biol. 2019 Oct;61(4):417-428. (PMID: 31264905)
Biol Proced Online. 2019 Oct 1;21:19. (PMID: 31582911)
Nat Rev Microbiol. 2022 Feb;20(2):95-108. (PMID: 34522050)
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. (PMID: 38572751)
PeerJ. 2020 Mar 19;8:e8806. (PMID: 32219032)
Cytojournal. 2022 Apr 30;19:28. (PMID: 35673697)
J Med Virol. 2015 Sep;87(9):1578-86. (PMID: 25880030)
Oncol Lett. 2020 Dec;20(6):357. (PMID: 33133257)
Cytojournal. 2022 Mar 29;19:23. (PMID: 35510117)
J Alzheimers Dis. 2021;79(1):249-265. (PMID: 33252074)
Int J Endocrinol. 2015;2015:250542. (PMID: 26273293)
Oncol Rep. 2019 Apr;41(4):2351-2360. (PMID: 30720133)
J Natl Cancer Cent. 2024 Feb 02;4(1):47-53. (PMID: 39036382)
Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):1983-1992. (PMID: 32699080)
Methods. 2021 Mar;187:104-113. (PMID: 32645449)
Cancer Cytopathol. 2018 Aug;126(8):533-540. (PMID: 29975461)
BMJ Glob Health. 2023 Jun;8(6):. (PMID: 37308263)
Int J Gynecol Pathol. 2023 Jan 1;42(1):11-20. (PMID: 35443260)
Oncotarget. 2016 Aug 23;7(34):55110-55127. (PMID: 27391153)
Elife. 2021 Nov 19;10:. (PMID: 34796874)
Int J Oncol. 2013 May;42(5):1569-77. (PMID: 23545944)
BMC Cancer. 2016 Mar 10;16:206. (PMID: 26965049)
Genet Mol Res. 2017 May 10;16(2):. (PMID: 28510248)
Noncoding RNA. 2017 Feb 20;3(1):. (PMID: 29657281)
Cancer Lett. 2021 May 28;506:120-127. (PMID: 33684533)

YJXK-2021-11 Hospital-level disciplines-Chronic disease Group-Cervical Diagnosis and Treatment Centre and obstetrics Endocrinology; YJXK-2021-11 Hospital-level disciplines-Chronic disease Group-Cervical Diagnosis and Treatment Centre and obstetrics Endocrinology; YJXK-2021-11 Hospital-level disciplines-Chronic disease Group-Cervical Diagnosis and Treatment Centre and obstetrics Endocrinology; YJXK-2021-11 Hospital-level disciplines-Chronic disease Group-Cervical Diagnosis and Treatment Centre and obstetrics Endocrinology; YJXK-2021-11 Hospital-level disciplines-Chronic disease Group-Cervical Diagnosis and Treatment Centre and obstetrics Endocrinology; YJXK-2021-11 Hospital-level disciplines-Chronic disease Group-Cervical Diagnosis and Treatment Centre and obstetrics Endocrinology; YJXK-2021-11 Hospital-level disciplines-Chronic disease Group-Cervical Diagnosis and Treatment Centre and obstetrics Endocrinology

Keywords: CAPZB; Cervical cancer; DNA methylation; Fluorescence in situ hybridization; Messenger RNA

0 (RNA, Messenger)
0 (Biomarkers, Tumor)
0 (CapZ Actin Capping Protein)

Date Created: 20240829 Date Completed: 20240829 Latest Revision: 20240903

20240903

PMC11362286

10.1038/s41598-024-71112-z

39209986